Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Short term Debt (2020 - 2022)

Historic Short term Debt for Anika Therapeutics (ANIK) over the last 7 years, with Q2 2022 value amounting to $4.3 million.

  • Anika Therapeutics' Short term Debt fell 7442.21% to $4.3 million in Q2 2022 from the same period last year, while for Jun 2022 it was $4.3 million, marking a year-over-year decrease of 7442.21%. This contributed to the annual value of $4.3 million for FY2021, which is 6703.59% down from last year.
  • Per Anika Therapeutics' latest filing, its Short term Debt stood at $4.3 million for Q2 2022, which was down 7442.21% from $4.3 million recorded in Q1 2022.
  • Over the past 5 years, Anika Therapeutics' Short term Debt peaked at $24.8 million during Q1 2021, and registered a low of $4.3 million during Q3 2021.
  • Moreover, its 3-year median value for Short term Debt was $4.3 million (2021), whereas its average is $10.3 million.
  • As far as peak fluctuations go, Anika Therapeutics' Short term Debt plummeted by 6703.59% in 2021, and later crashed by 8268.22% in 2022.
  • Anika Therapeutics' Short term Debt (Quarter) stood at $13.1 million in 2020, then crashed by 67.04% to $4.3 million in 2021, then changed by 0.0% to $4.3 million in 2022.
  • Its last three reported values are $4.3 million in Q2 2022, $4.3 million for Q1 2022, and $4.3 million during Q4 2021.